Stone Pharmaceuticals Innovation: Application for the marketing approval of Sijikuiyoudankang injection has been accepted.

ShiYao Innovation announced that its holding subsidiary, ShiYao Group Jushi Biopharmaceutical Co., Ltd., recently received the "Acceptance Notice" issued by the National Medical Products Administration, indicating that the application for the listing of Surufatoxumab Injection has been accepted.